ERBB2 and breast cancer: To address this issue, a questionnaire was designed to ask clinicians who had recruited patients into Persephone about their current clinical beliefs of the effectiveness and cardiotoxicity profile of 6 and 12 months adjuvant trastuzumab treatment in the HER2 breast cancer setting.